Francisco M Cruz1, David Sanz-Rosa2, Marta Roche-Molina1, Jaime García-Prieto2, José M García-Ruiz2, Gonzalo Pizarro2, Luis J Jiménez-Borreguero2, Miguel Torres1, Antonio Bernad1, Jesús Ruíz-Cabello3, Valentín Fuster4, Borja Ibáñez5, Juan A Bernal6. 1. Cardiovascular Development and Repair Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. 2. Epidemiology, Atherothrombosis and Imaging Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. 3. Advanced Imaging Unit, Epidemiology, Atherothrombosis and Imaging Department, Ciber de Enfermedades Respiratorias and Universidad Complutense, Madrid, Spain. 4. Epidemiology, Atherothrombosis and Imaging Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York. 5. Epidemiology, Atherothrombosis and Imaging Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain. Electronic address: bibanez@cnic.es. 6. Cardiovascular Development and Repair Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. Electronic address: jabernal@cnic.es.
Abstract
BACKGROUND: Exercise has been proposed as a trigger for arrhythmogenic right ventricular cardiomyopathy (ARVC) phenotype manifestation; however, research is hampered by the limited availability of animal models in which disease-associated mutations can be tested. OBJECTIVES: This study evaluated the impact of exercise on ARVC cardiac manifestations in mice after adeno-associated virus (AAV)-mediated gene delivery of mutant human PKP2, which encodes the desmosomal protein plakophilin-2. METHODS: We developed a new model of cardiac tissue-specific transgenic-like mice on the basis of AAV gene transfer to test the potential of a combination of a human PKP2 mutation and endurance training to trigger an ARVC-like phenotype. RESULTS: Stable cardiac expression of mutant PKP2 (c.2203C>T), encoding the R735X mutant protein, was achieved 4 weeks after a single AAV9-R735X intravenous injection. High-field cardiac magnetic resonance over a 10-month postinfection follow-up did not detect an overt right ventricular (RV) phenotype in nonexercised (sedentary) mice. In contrast, endurance exercise training (initiated 2 weeks after AAV9-R735X injection) resulted in clear RV dysfunction that resembled the ARVC phenotype (impaired global RV systolic function and RV regional wall motion abnormalities on cardiac magnetic resonance). At the histological level, RV samples from endurance-trained R735X-infected mice displayed connexin 43 delocalization at intercardiomyocyte gap junctions, a change not observed in sedentary mice. CONCLUSIONS: The introduction of the PKP2 R735X mutation into mice resulted in an exercise-dependent ARVC phenotype. The R735X mutation appears to function as a dominant-negative variant. This novel system for AAV-mediated introduction of a mutation into wild-type mice has broad potential for study of the implication of diverse mutations in complex cardiomyopathies.
BACKGROUND: Exercise has been proposed as a trigger for arrhythmogenic right ventricular cardiomyopathy (ARVC) phenotype manifestation; however, research is hampered by the limited availability of animal models in which disease-associated mutations can be tested. OBJECTIVES: This study evaluated the impact of exercise on ARVC cardiac manifestations in mice after adeno-associated virus (AAV)-mediated gene delivery of mutant humanPKP2, which encodes the desmosomal protein plakophilin-2. METHODS: We developed a new model of cardiac tissue-specific transgenic-like mice on the basis of AAV gene transfer to test the potential of a combination of a humanPKP2 mutation and endurance training to trigger an ARVC-like phenotype. RESULTS: Stable cardiac expression of mutant PKP2 (c.2203C>T), encoding the R735X mutant protein, was achieved 4 weeks after a single AAV9-R735X intravenous injection. High-field cardiac magnetic resonance over a 10-month postinfection follow-up did not detect an overt right ventricular (RV) phenotype in nonexercised (sedentary) mice. In contrast, endurance exercise training (initiated 2 weeks after AAV9-R735X injection) resulted in clear RV dysfunction that resembled the ARVC phenotype (impaired global RV systolic function and RV regional wall motion abnormalities on cardiac magnetic resonance). At the histological level, RV samples from endurance-trained R735X-infected mice displayed connexin 43 delocalization at intercardiomyocyte gap junctions, a change not observed in sedentary mice. CONCLUSIONS: The introduction of the PKP2R735X mutation into mice resulted in an exercise-dependent ARVC phenotype. The R735X mutation appears to function as a dominant-negative variant. This novel system for AAV-mediated introduction of a mutation into wild-type mice has broad potential for study of the implication of diverse mutations in complex cardiomyopathies.
Authors: Antonio Rodríguez-Sinovas; Jose Antonio Sánchez; Laura Valls-Lacalle; Marta Consegal; Ignacio Ferreira-González Journal: Int J Mol Sci Date: 2021-04-23 Impact factor: 5.923
Authors: Jason D Roberts; Nathaniel P Murphy; Robert M Hamilton; Ellen R Lubbers; Cynthia A James; Crystal F Kline; Michael H Gollob; Andrew D Krahn; Amy C Sturm; Hassan Musa; Mona El-Refaey; Sara Koenig; Meriam Åström Aneq; Edgar T Hoorntje; Sharon L Graw; Robert W Davies; Muhammad Arshad Rafiq; Tamara T Koopmann; Shabana Aafaqi; Meena Fatah; David A Chiasson; Matthew Rg Taylor; Samantha L Simmons; Mei Han; Chantal Jm van Opbergen; Loren E Wold; Gianfranco Sinagra; Kirti Mittal; Crystal Tichnell; Brittney Murray; Alberto Codima; Babak Nazer; Duy T Nguyen; Frank I Marcus; Nara Sobriera; Elisabeth M Lodder; Maarten P van den Berg; Danna A Spears; John F Robinson; Philip C Ursell; Anna K Green; Allan C Skanes; Anthony S Tang; Martin J Gardner; Robert A Hegele; Toon Ab van Veen; Arthur Am Wilde; Jeff S Healey; Paul Ml Janssen; Luisa Mestroni; J Peter van Tintelen; Hugh Calkins; Daniel P Judge; Thomas J Hund; Melvin M Scheinman; Peter J Mohler Journal: J Clin Invest Date: 2019-07-02 Impact factor: 14.808
Authors: Sjoerd M Verwijs; Yigal M Pinto; Diederik W D Kuster; Jolanda van der Velden; Jacqueline Limpens; Juliette C van Hattum; Saskia N van der Crabben; Ronald H Lekanne Deprez; Arthur A M Wilde; Harald T Jørstad Journal: Cardiology Date: 2021-10-27 Impact factor: 1.869